Sponsor Directory

Genentech, Inc. clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1396

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions: Ibrutinib, Obinutuzumab, Venetoclax; Drug · Biological
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Fresno, California • Los Angeles, California • Sacramento, California + 1 more

Conditions: Endometrial Cancer, Uterine Carcinosarcoma
Interventions: Rucaparib, Bevacizumab, Atezolizumab; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 3
States / cities: New York, New York • Bethlehem, Pennsylvania • Milwaukee, Wisconsin

Conditions: Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Atezolizumab, Temozolomide; Biological · Drug
Lead sponsor: Dwight Owen; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more

Conditions: Lung Cancer, NSCLC, Brain Metastases
Interventions: Alectinib, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: Joshua Palmer; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Columbus, Ohio

Conditions: Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
Interventions: Emicizumab; Drug
Lead sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois; Other
Eligibility: 0 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 12
States / cities: Orange, California • Redwood City, California • Coral Gables, Florida + 9 more

Conditions: STEMI - ST Elevation Myocardial Infarction
Interventions: Telehealth; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 30 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Follicular Lymphoma
Interventions: Mosunetuzumab, Tazemetostat Pill; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
Interventions: Venetoclax, Tazemetostat; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Basal Cell Carcinoma
Interventions: Vismodegib 150 MG Oral Capsule; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer Metastatic
Interventions: Stereotactic body radiation therapy (SBRT), Atezolizumab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: Tampa, Florida • Hilliard, Ohio

Conditions: Schizo-Affective Type of Psychosis, Schizophrenia
Interventions: Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram, Ocrelizumab infusion; Behavioral · Diagnostic Test · Biological
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 35 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endometrial Cancer
Interventions: Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab emtansine, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, Letrozole, Giredestrant, Abemaciclib; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 21
States / cities: Duarte, California • San Francisco, California • Washington D.C., District of Columbia + 18 more

About this Genentech, Inc. sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Genentech, Inc. clinical trials

Filter and sort this sponsor

Live official records

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Emergency Medical Services (EMS) Telehealth to Speed STEMI Reperfusion

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Ocrelizumab for Psychosis by Autoimmunity

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

About this Genentech, Inc. sponsor directory page